Compare AQST & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AQST | CGEM |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.6M | 671.7M |
| IPO Year | 2018 | 2021 |
| Metric | AQST | CGEM |
|---|---|---|
| Price | $3.92 | $10.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $8.83 | ★ $28.13 |
| AVG Volume (30 Days) | ★ 4.3M | 983.3K |
| Earning Date | 11-05-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $43,397,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.12 | $5.68 |
| 52 Week High | $7.55 | $13.33 |
| Indicator | AQST | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 22.22 | 55.31 |
| Support Level | $5.86 | $9.41 |
| Resistance Level | $6.59 | $10.70 |
| Average True Range (ATR) | 0.32 | 0.63 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 11.98 | 67.58 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.